Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

The Novavax vaccine targets the same XBB.1.5 variant as the other two vaccines. That variant was the dominant one in the U.S. earlier this year when the FDA had to choose the makeup of this fall's ...

Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022.

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

Novavax’s UK trial, with more than 15,000 participants ages 18 to 84, found that the vaccine had an efficacy of 96.4% against mild, moderate and severe disease caused by the original coronavirus ...

Novavax, a small biotech company in Maryland, garnered attention June 18 when it announced its vaccine candidate is more than 90% effective overall and 100% effective at preventing moderate to ...

Novavax has been working on developing vaccines for more than three decades, but hasn’t brought one to market. The company’s COVID-19 vaccine work is partly funded by the U.S. government.

The Novavax vaccine was one of the vaccines chosen for development as part of Operation Warp Speed. The U.S. government is providing $1.75 billion to the company to support the vaccine's development.